Rolf Luft Research Center for Diabetes and Endocrinology, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Rolf Luft Research Center for Diabetes and Endocrinology, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden ; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden.
Clin Epigenetics. 2014 May 30;6(1):10. doi: 10.1186/1868-7083-6-10. eCollection 2014.
Clinical observations have demonstrated that high levels of circulating insulin-like growth factor binding protein-1 (IGFBP-1) are associated with type 1 diabetes (T1D), whereas low serum IGFBP-1 levels are associated with the risk of type 2 diabetes (T2D). Recently, we reported that increased DNA methylation levels in the IGFBP1 gene were associated with T2D. In the present study, we evaluated the epigenetic changes of IGFBP1 in T1D and diabetic nephropathy (DN).
In total, 778 Swedish individuals, including T1D patients with or without DN and subjects with the normal glucose tolerance (NGT), were involved in the study. IGFBP1 methylation levels in genomic DNA extracted from peripheral blood were analyzed with bisulfite pyrosequencing. Serum IGFBP-1 levels were measured with radioimmunoassay. We found that DNA methylation levels in the IGFBP1 gene were decreased (15.6% versus 16.9%; P < 0.001), whereas serum IGFBP-1 levels were increased (31 versus 24 μg/L, P = 0.003) in T1D patients compared with NGT subjects. Furthermore, T1D patients with DN had increased circulating IGFBP-1 concentration compared with the patients without DN (52 versus 28 μg/L; P = 0.006). However, no difference of the IGFBP1 DNA methylation levels between T1D patients with and without DN was observed.
This study shows for the first time that T1D patients had decreased DNA methylation levels in the IGFBP1 gene and further implies that increased circulating IGFBP-1 levels are associated with T1D and DN.
临床观察表明,循环胰岛素样生长因子结合蛋白-1(IGFBP-1)水平升高与 1 型糖尿病(T1D)有关,而血清 IGFBP-1 水平降低与 2 型糖尿病(T2D)的风险相关。最近,我们报道 IGFBP1 基因中 DNA 甲基化水平的增加与 T2D 有关。在本研究中,我们评估了 IGFBP1 在 T1D 和糖尿病肾病(DN)中的表观遗传变化。
共有 778 名瑞典人参与了这项研究,包括 T1D 患者(有或无 DN)和糖耐量正常(NGT)的受试者。用亚硫酸氢盐焦磷酸测序法分析外周血基因组 DNA 中 IGFBP1 的甲基化水平。用放射免疫法测量血清 IGFBP-1 水平。我们发现,与 NGT 受试者相比,T1D 患者的 IGFBP1 基因 DNA 甲基化水平降低(15.6%比 16.9%;P<0.001),而血清 IGFBP-1 水平升高(31 比 24μg/L,P=0.003)。此外,与无 DN 的 T1D 患者相比,DN 的 T1D 患者的循环 IGFBP-1 浓度更高(52 比 28μg/L;P=0.006)。然而,在有和无 DN 的 T1D 患者之间,IGFBP1 基因的 DNA 甲基化水平没有差异。
本研究首次表明,T1D 患者的 IGFBP1 基因 DNA 甲基化水平降低,进一步表明循环 IGFBP-1 水平升高与 T1D 和 DN 有关。